Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118104 | 1.00 | CDC25B (0.47) | CDC25BGFERHSD17B10MEN1KMT2A | |
| SCHEMBL30838597 | 0.85 | ESR1 (0.40) | CDC25BMEN1KMT2ACA12CA9 | |
| SCHEMBL2185926 | 0.84 | CDC25B (0.56) | CDC25BGFERHSD17B10MEN1KMT2A | |
| SCHEMBL3390578 | 0.82 | GRIN2D (0.51) | CDC25BHSD17B10MEN1KMT2AGRIN2D | |
| SCHEMBL29903129 | 0.81 | IDO1 (0.43) | HSD17B10MEN1KMT2AGRIN2DGRIN2A | |
| SCHEMBL29903128 | 0.81 | IDO1 (0.43) | HSD17B10MEN1KMT2AGRIN2DGRIN2A | |
| SCHEMBL23409308 | 0.81 | IDO1 (0.43) | HSD17B10MEN1KMT2AGRIN2DGRIN2A | |
| SCHEMBL29937467 | 0.80 | HSD17B10 (0.64) | CDC25BHSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL1619337 | 0.80 | HSD17B10 (0.64) | CDC25BHSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL19202322 | 0.79 | POLB (0.45) | HSD17B10MEN1KMT2AGRIN2DGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003677-B | Compounds having inhibitory activity against KRAS G12D mutations | 大鹏药品工业株式会社 | 2024-08-27 | — | — | CN | disclosed |
| EP-4347041-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | Taiho Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | ASTEX THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| WO-2022250170-A9 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022250170-A9 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-05 | — | — | WO | disclosed |
| EP-4065583-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-10-05 | — | — | EP | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021106231-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021107160-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | KRAS, NRAS, HRAS | CDC25B 471/4885GFER 4409/4885HSD17B10 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.